PDCD1 and glioblastoma: The discrepancy in clinical responses between standard therapy and anti-PD1 treatment in GBM implied that patients in immune cluster 2 might not obtain clinical benefits from standard therapy but could benefit from immunotherapy including anti-PD1, with elevated antigen processing and presentation with T-cell activation under treatment.